


AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently amended). A compound of formula (I)



wherein

Z is selected from O, S, N, OH, or Cl, with the provisos that when Z is O or S, R⁴¹ is absent; ~~and~~ when Z is OH or Cl, both R⁴¹ and R⁴² are absent and when Z is N, R⁴¹ is hydrogen or loweralkyl;

X and Y are independently selected from O, OCO, S, SO, SO₂, CO, CO₂, NR¹⁰, NR¹¹CO, NR¹²CONR¹³, NR¹⁴CO₂, NR¹⁵SO₂, NR¹⁶SO₂NR¹⁷, SO₂NR¹⁸, CONR¹⁹, halogen, nitro, cyano, or X or Y are absent;

R¹ is hydrogen, CH₃, OH, OCH₃, SH, SCH₃, OCOR²¹, SOR²², SO₂R²³, SO₂NR²⁴R²⁵, CO₂R²⁶, CONR²⁷R²⁸, NH₂, NR²⁹SO₂NR³⁰R³¹, NR³²SO₂R³³, NR³⁴COR³⁵, NR³⁶CO₂R³⁷, NR³⁸CONR³⁹R⁴⁰, halogen, nitro, or cyano;

R² and R³ are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heterocycloalkyl or substituted heterocycloalkyl; with the proviso that when X is halo, nitro or cyano, R² is absent, and, when Y is halo, nitro or cyano, R³ is absent;


R⁶ is H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, NR⁷R⁸, OR⁹ or halogen;

R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²¹, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹,

R^{30} , R^{31} , R^{32} , R^{34} , R^{35} , R^{36} , R^{38} , R^{39} and R^{40} are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclo, or substituted heterocyclo;

R^{22} , R^{23} , R^{33} and R^{37} are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclo, or substituted heterocyclo;

R^{42} is



$(R^{43})_n$ wherein n equals 0, 1 or 2 and each R^{43} is independently selected from the group consisting of hydrogen, fluorine, chlorine and methyl; and

R^{44} is methyl, or hydrogen,

with the further provisos that:

- a. R^2 may not be hydrogen if X is SO , SO_2 , $NR^{13}CO_2$, or $NR^{14}SO_2$; and
- b. R^3 may not be hydrogen if Y is SO , SO_2 , $NR^{13}CO_2$, or $NR^{14}SO_2$;

or an enantiomer, diastereomer, or pharmaceutically acceptable salt, ~~prodrug, or solvate~~ thereof,

Claim 2 (Original). A compound according to claim 1 wherein R^1 is hydrogen or methyl; R^6 is hydrogen; R^3 is lower alkyl; and Z is oxygen or nitrogen.

Claim 3 (Original). A compound according to claim 1 wherein R^1 is hydrogen; R^3 is lower alkyl; Y is absent; X is oxygen or nitrogen; R^{43} is fluoro or hydrogen; and R^{44} is hydrogen or methyl.

Claim 4 (Original). A compound according to claim 1 wherein X is oxygen; R^2 is a substituted alkyl and R^{43} is fluoro.

Claim 5 (Original). A compound according to claim 1 wherein X is absent; R² is a substituted hetrocyclo, substituted heterocyclo, heteroaryl or substituted heteroaryl, and Z is nitrogen.

Claim 6 (Original). A compound selected from the group consisting of
4-(4-Fluoro-*1H*-pyrrolo[2,3-*b*]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-*f*][1,2,4]triazin-6-ol,
(*R*)-1-[4-(4-Fluoro-*1H*-pyrrolo[2,3-*b*]pyridin-5-yloxy)-5-methylpyrrolo[2,1-*f*][1,2,4]triazin-6-yloxy]-propan-2-ol,
(*S*)-1-[4-(4-Fluoro-*1H*-pyrrolo[2,3-*b*]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-*f*][1,2,4]triazin-6-yloxy]-propan-2-ol,
(*R*)-1-[4-(4-Fluoro-2-methyl-*1H*-pyrrolo[2,3-*b*]pyridin-5-yloxy)-5-methyl-pyrrolo[2,1-*f*][1,2,4]triazin-6-yloxy]-propan-2-ol,
(*R*)-2-[4-(4-Fluoro-*1H*-pyrrolo[2,3-*b*]pyridin-5-yloxy)-5-methylpyrrolo[2,1-*f*][1,2,4]triazin-6-yloxy]-1-methylethylamine,
(*R*)-2-[4-(4-Fluoro-2-methyl-*1H*-pyrrolo[2,3-*b*]pyridin-5-yloxy)-5-methylpyrrolo[2,1-*f*][1,2,4]triazin-6-yloxy]-1-methyl-ethylamine,
2-[4-(4-Fluoro-*1H*-pyrrolo[2,3-*b*]pyridin-5-yloxy)-5-methylpyrrolo[2,1-*f*][1,2,4]triazin-6-yloxy]-ethylamine,
(4-Fluoro-*1H*-pyrrolo[2,3-*b*]pyridin-5-yl)-[5-isopropyl-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrrolo[2,1-*f*][1,2,4]triazin-4-yl]-amine,
(4-Fluoro-*1H*-pyrrolo[2,3-*b*]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-*f*][1,2,4]triazin-4-yl]-amine,
(4-Fluoro-2-methyl-*1H*-pyrrolo[2,3-*b*]pyridin-5-yl)-[5-isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-*f*][1,2,4]triazin-4-yl]-amine, and
[5-Isopropyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrrolo[2,1-*f*][1,2,4]triazin-4-yl]-(2-methyl-*1H*-pyrrolo[2,3-*b*]pyridin-5-yl)-amine.

Claim 7 (Currently amended). A pharmaceutical composition comprising ~~at least one~~ one or more of the compounds of Claim 1 and a pharmaceutically acceptable carrier therefor.

Claim 8 (Currently amended). A pharmaceutical composition comprising ~~at least one~~ one or more of the compounds of Claim 6 and a pharmaceutically acceptable carrier therefor.

Claim 9 (Currently amended). A pharmaceutical composition comprising ~~at least one~~ one or more compounds of Claim 1 in combination with a pharmaceutically acceptable carrier and ~~at least one~~ one or more additional anti-cancer or cytotoxic agent.

Claim 10 (Currently amended). A pharmaceutical composition comprising ~~at least one~~ one or more compounds of Claim 6 in combination with a pharmaceutically acceptable carrier and ~~at least one~~ one or more additional anti-cancer or cytotoxic agent.

Claim 11 (Currently amended). The pharmaceutical composition of Claim ~~7-9~~ 9, wherein said anti-cancer or cytotoxic agent is selected from the group consisting of: linomide, inhibitors of integrin $\alpha v \beta 3$ function, angiostatin, razoxane, tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, herceptin, metalloproteinase inhibitors, inhibitors of urokinase plasminogen activator receptor function, growth factor antibodies, growth factor receptor antibodies, bevacizumab, cetuximab, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, methotrexate, 5-fluorouracil, purine, adenosine analogues, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa, vincristine, paclitaxel, docetaxel, epothilone analogs, discodermolide analogs, eleutherobin analogs, etoposide, teniposide, amsacrine, topotecan, irinotecan, flavopyridols, ~~proteasome inhibitors including~~ bortezomib and biological response modifiers.

Claim 12 (Currently amended). A method for producing an antiangiogenic effect which comprises administering to a mammalian species in need thereof, an effective antiangiogenic producing amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 13 (Currently amended). A method for producing a vascular permeability reducing effect which comprises administering to a mammalian species in need thereof an effective vascular permeability reducing amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 14 (Currently amended). A method of inhibiting protein kinase activity of growth factor receptors which comprises administering to a mammalian species in need thereof, an effective protein kinase inhibiting amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 15 (Currently amended). A method of inhibiting tyrosine kinase activity of growth factor receptors which comprises administering to a mammalian species in need thereof, an effective tyrosine kinase inhibiting amount of ~~at least one~~ one or more of the compounds of Claim 1.

Claim 16 (Canceled). A method for treating proliferative diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of the composition of Claim 7.

Claim 17 (Canceled). A method for treating cancer, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of the composition of Claim 7.

Claim 18 (Canceled). A method for treating inflammation, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of the composition of Claim 7.

Claim 19 (Canceled). A method for treating autoimmune diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of the composition of Claim 7.

Claim 20 (Canceled). A method for treating diseases associated with signal transduction pathways operating through growth factor receptors, which comprises administering to a mammalian species in need thereof a therapeutically effective amount of at least one of the compounds of Claim 1.